Category: Vector Manufacturing

Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level,  the demand for such therapies has increased considerably over the past few years. Currently, more than 285 gene therapies are being evaluated in different phases of clinical development. Further, various gene therapy developers have raised more than USD 10 billion

The concept of modular building has long been employed in other sectors, but it has only recently acquired traction in the pharmaceutical business over the last two to three decades. Modular construction is a process wherein factory-produced, pre-engineered building units, which are constructed offsite under controlled plant conditions, are assembled on site to construct the

The recent years have portrayed the renaissance in the domain of biologics, as pharmaceutical industry has once again gained attention towards the production of bioproducts. In fact, in 2019, a total of 28 biopharmaceutical products (including monoclonal antibodies, recombinant proteins and gene therapies) were approved in the US. Further, over 8,000 biological pharmaceutical products are

With close to half-million infections and the economy showing signs of the 2008 financial crisis, COVID-19 has impacted several industries. Government institutes and industry players have announced various steps to deal with the ongoing situation. In this article, we will highlight the developments in the cell and gene therapy manufacturing industry amid the ongoing COVID-19

The growing pipeline of cell and gene therapies has led to an increase in demand for high-quality gene delivery vehicles and, therefore, has created significant opportunities for companies with expertise in manufacturing viral and non-viral vectors. In an article published last year, I discussed the growing cell and gene therapy market and how it has